This clinical trial is focused on patients who have undergone a type of abdominal surgery called a longitudinal laparotomy. The study is investigating the effectiveness of a medication called oral lidocaine, also known by its code name ORE-001, in preventing gastrointestinal issues that can occur after this surgery. These issues can include discomfort or intolerance in the digestive system, as well as a condition known as postoperative ileus, where the intestines do not function properly after surgery.

The purpose of the study is to see if oral lidocaine can help reduce these gastrointestinal problems compared to a placebo, which is a tablet that looks like the medication but does not contain any active ingredients. Participants in the study will be randomly assigned to receive either the oral lidocaine or the placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will be monitored for changes in their gastrointestinal symptoms, using a scoring system called the I-FEED score, which helps measure the severity of these symptoms. The study will track these scores at various points after surgery to determine the effectiveness of the treatment. The study will also monitor for any side effects or adverse events that may occur during the treatment period. The goal is to gather information that could lead to better management of gastrointestinal issues following abdominal surgery.